Corcept Therapeutics CORT Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 98.3%-0.2pp | 98.3%-0.1pp | 98.2%-0.2pp | 98.4%-0.1pp | 98.4%-0.1pp | |
| Operating margin | -1.1%-17.2pp | 5.9%-14.4pp | 8.8%-14.0pp | 14.2%-8.2pp | 16.2%-7.1pp | |
| Net margin | 6.2%-13.4pp | 13.1%-7.8pp | 14.3%-8.2pp | 18.7%-3.5pp | 19.5%-3.0pp | |
| EBITDA margin | -0.9%-17.2pp | 6%-14.4pp | 9%-13.9pp | 14.4%-8.2pp | 16.3%-7.1pp | |
| Free cash flow margin | 15.6%-10.2pp | 18.6%-10.4pp | 22%-0.5pp | 25.2%+3.6pp | 25.8%+2.1pp | |
| Returns | ||||||
| Return on equity | 7.2%-14.6pp | 15%-8.8pp | 16.7%-9.1pp | 21.7%-3.1pp | 21.8%-0.1pp | |
| Return on assets | 5.7%-12.1pp | 11.9%-7.4pp | 13.2%-7.4pp | 17.6%-2.7pp | 17.8%-0.7pp | |
| Return on invested capital | -1.4%-23.3pp | 8.2%-17.6pp | 12.8%-15.6pp | 20.1%-9.6pp | 21.9%-10.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | 0.9×+0.1× | |
| Inventory turnover | 1.7×-0.7× | 1.8×-0.1× | 1.4×+0.2× | 1.4×+0.4× | 2.4×+1.5× | |
| Liquidity | ||||||
| Current ratio | 2.9×-0.2× | 2.9×-0.4× | 3.1×-0.6× | 3.1×-2.5× | 3.1×-2.1× | |
| Quick ratio | 2.8×-0.3× | 2.9×-0.5× | 3.1×-0.6× | 3×-2.5× | 3.1×-2.0× | |
| Cash ratio | 0.7×+0.1× | 0.7×-0.2× | 0.7×-0.4× | 0.7×-0.6× | 0.6×-0.9× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $6.11+7.1% | $5.40-9.8% | $5.29-5.8% | $5.28-1.5% | $5.70+14.4% | |
| Valuation | ||||||
| Market capitalization | $4.29B-64.4% | $3.66B-30.7% | $8.76B+81.1% | $8.14B+141% | $12.05B+362% | |
| Enterprise value | $4.19B-65.0% | $3.54B-31.3% | $8.64B+83.6% | $8.04B+147% | $11.97B+387% | |
| Price / earnings | 90.6×+0.6× | 36.7×-0.7× | 82.5×+48.4× | 60.9×+34.1× | 89.9×+67.8× | |
| Price / sales | 5.6×-12.0× | 4.8×-3.0× | 11.8×+4.1× | 11.4×+5.4× | 17.6×+12.6× | |
| Price / book | 6.7×-10.9× | 5.7×-2.1× | 13.9×+6.3× | 12.8×+7.1× | 17.6×+12.9× | |
| EV / sales | 5.4×-12.0× | 4.7×-3.0× | 11.7×+4.2× | 11.2×+5.5× | 17.5×+12.8× | |
| Free cash flow yield | 2.8%+1.3pp | 3.9%+0.2pp | 1.9%-1.1pp | 2.2%-1.4pp | 1.5%-3.3pp | |
| Earnings yield | 1.1%0.0pp | 2.7%0.0pp | 1.2%-1.7pp | 1.6%-2.1pp | 1.1%-3.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Corcept Therapeutics's profit margins?
- Corcept Therapeutics (CORT) runs a 98.3% gross margin and a -1.1% operating margin, with a 6.2% net margin.
- Where do Corcept Therapeutics's ratios come from?
- Every ratio is computed from Corcept Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
